ストックスクリーナーアプリを入手
8.82
2.20%
0.19
Alumis Inc (ALMS) 最新ニュース
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor - Yahoo! Voices
Alumis (NASDAQ:ALMS) Given "Buy" Rating at HC Wainwright - MarketBeat
Alumis reports promising Phase 1 trial results for MS drug - Investing.com
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 - The Bakersfield Californian
Alumis Reports Breakthrough Clinical Data: TYK2 Drug Shows Strong Brain Penetration in Phase 1 Trial - StockTitan
Charles Schwab Investment Management Inc. Takes $1.16 Million Position in Alumis Inc. (NASDAQ:ALMS) - Defense World
Charles Schwab Investment Management Inc. Invests $1.16 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc.’s (NASDAQ:ALMS) Lock-Up Period Set To Expire on December 25th - Defense World
Alumis Inc.'s (NASDAQ:ALMS) Lock-Up Period Will Expire on December 25th - MarketBeat
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Pre-market Movers: LOOP, RPTX, CADL, INO, ISPC… - RTTNews
(ALMS) Technical Data - Stock Traders Daily
Alumis Inc. (NASDAQ:ALMS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Samsara BioCapital LLC Acquires Shares of 3,266,498 Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics - Quantisnow
How the (ALMS) price action is used to our Advantage - Stock Traders Daily
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Ally Bridge Group NY LLC Cuts Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis: A Best-In-Class TYK2 Inhibitor (NASDAQ:ALMS) - Seeking Alpha
Alumis updates clinical trial dates for lupus study By Investing.com - Investing.com Australia
Alumis updates clinical trial dates for lupus study - Investing.com
Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs - MSN
Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online
What is HC Wainwright's Forecast for Alumis FY2024 Earnings? - MarketBeat
Leerink Partnrs Has Weak Estimate for Alumis FY2024 Earnings - MarketBeat
HC Wainwright Lowers Alumis (NASDAQ:ALMS) Price Target to $26.00 - Defense World
Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 - The Manila Times
Alumis' ESK-001 Shows Promise in Lupus Treatment, New Clinical Data Revealed at ACR 2024 | ALMS Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
Towerview LLC Buys 70,000 Shares of Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Price Target Lowered to $26.00 at HC Wainwright - MarketBeat
Alumis (NASDAQ:ALMS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Reports 93% Success in Psoriasis Trial, Q3 Loss Widens to $93.1M | ALMS Stock News - StockTitan
Telsey Advisory Group Predicts Reduced Earnings for FIGS - Defense World
Analysts Set Alumis Inc. (NASDAQ:ALMS) Price Target at $27.50 - MarketBeat
U.S. Energy (NASDAQ:USEG) Earns Sell Rating from Analysts at StockNews.com - Defense World
Chase (NYSE:CCF) Coverage Initiated by Analysts at StockNews.com - Defense World
CGI Inc. (NYSE:GIB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug - MSN
Uveitis Clinical Trials 2024: FDA Approvals, Medication, - openPR
How to Take Advantage of moves in (ALMS) - Stock Traders Daily
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD - Quantisnow
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - StockTitan
Net Present Value Model: Alumis Inc’s ESK-001 - GlobalData
Alumis (NASDAQ:ALMS) Rating Increased to Strong-Buy at Baird R W - MarketBeat
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Robert W. Baird Begins Coverage on Alumis (NASDAQ:ALMS) - MarketBeat
Baird starts Alumis coverage with Outperform, $25 target - Investing.com India
Baird starts Alumis coverage with Outperform, $25 target By Investing.com - Investing.com South Africa
When (ALMS) Moves Investors should Listen - Stock Traders Daily
Blue Trust Inc. Purchases 307 Shares of Watsco, Inc. (NYSE:WSO) - Defense World
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - MSN
Alumis (NASDAQ:ALMS) Stock Price Down 4.5%Time to Sell? - MarketBeat
Alumis (NASDAQ:ALMS) Trading 3.1% HigherWhat's Next? - MarketBeat
HC Wainwright Predicts Alumis' Q3 Earnings (NASDAQ:ALMS) - MarketBeat
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):